Supernus Pharmaceuticals Inc. (SUPN)
Market Closed
17 Jul, 20:00
$
48. 04
-0.17
-0.3526%
$
2.81B Market Cap
64.88 P/E Ratio
- Div Yield
439,400 Volume
2.16 Eps
$ 48.21
Previous Close Want to track SUPN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
SUPN closed today lower at $48.04, a decrease of -0.3526% from yesterday's close, completing a monthly increase of 4.8222% or $2.21. Over the past 12 months, SUPN stock lost -3.34%.
SUPN is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, missed the consensus estimates by -0.26%. On average, the company has surpassed earnings expectations by 0.2266%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).
SUPN Chart
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks | 1 week ago
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seekingalpha | 2 months ago
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Seekingalpha | 2 months ago
Supernus Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 80 | $2,730.4 | $3,754.84 | $1,024.44 | 37.52% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 68,825 | $2.3M | $3.23M | $936,793.07 | 40.77% |
 Farallon Capital Farallon Capital Management LLC | 4,000 | $206,760 | $187,986.8 | -$18,773.2 | -9.08% |
| BG Bart Gancher Intech Investment Management LLC | 38,984 | $1.71M | $1.83M | $127,486.05 | 7.47% |
 Robert Bruce Robert Jeffrey Bruce is VP/Secretary at Bruce & Co Inc. | 100,000 | $2.94M | $4.7M | $1.76M | 59.7% |
Supernus Pharmaceuticals Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Kristen Kluska Cantor Fitzgerald | 625.39 | $30,487.8 | $30,150.09 | -$337.71 | -1.11% |
Supernus Pharmaceuticals Inc. (SUPN) FAQ
What is the stock price today?
The current price is $48.04.
On which exchange is it traded?
Supernus Pharmaceuticals Inc. is listed on NASDAQ (NMS).
What is its stock symbol?
The ticker symbol is SUPN.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 2.81B.
Has Supernus Pharmaceuticals Inc. ever had a stock split?
No, there has never been a stock split.
Supernus Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Jack A. Khattar CEO | NASDAQ (NMS) Exchange | 868459108 CUSIP |
| US Country | 674 Employees | - Last Dividend | - Last Split | 1 May 2012 IPO Date |
Overview
Supernus Pharmaceuticals, Inc. is a biopharmaceutical enterprise dedicated to addressing the complex challenges of central nervous system (CNS) diseases within the United States. Since its inception in 2005, based in Rockville, Maryland, Supernus has committed itself to the development and commercialization of innovative and effective treatments aimed at improving the quality of life for patients suffering from a broad range of CNS conditions. Its strategic approach involves a comprehensive research and development program, coupled with extensive clinical trials to ensure the efficacious and safe application of its products.
Products and Services
- Trokendi XR: An extended-release formulation of topiramate, designed to treat epilepsy and prevent migraine headaches by delivering a steady dosage of medication over an extended period.
- Oxtellar XR: An extended-release version of oxcarbazepine that serves as monotherapy for partial-onset seizures in both adults and children aged 6 to 17 years, streamlining the management of epilepsy with once-daily dosing.
- Qelbree: A novel, non-stimulant medication approved for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older, offering a new therapeutic option without the same abuse potential as traditional stimulant drugs.
- APOKYN: Provides acute, intermittent treatment of hypomobility or 'off' episodes in patients with advanced Parkinson's Disease (PD), contributing significantly to the management of mobility-related fluctuations experienced by these patients.
- XADAGO: A medication used alongside levodopa/carbidopa in PD patients experiencing 'off' episodes, enhancing the control of motor symptoms and improving patients' quality of life.
- MYOBLOC: A Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults, showcasing the importance of targeted therapy in managing complex motor disorders.
- GOCOVRI: Approved for treating dyskinesia in patients with PD, this medication contributes to the broader effort to manage the side effects associated with long-term PD treatment.
- Osmolex ER: This extended-release medication is designed for the treatment of Parkinson's disease and drug-induced extrapyramial reactions in adult patients, illustrating the ongoing need for innovative PD management strategies.
- In development, Supernus boasts a portfolio of promising candidates, including SPN-830, a late-stage drug/device combination for 'off' episodes in PD; and SPN-817, a novel, first-in-class selective acetylcholinesterase inhibitor in Phase II trials for epilepsy. Other candidates like SPN-820, targeting resistant depression, and SPN-443 as well as SPN-446 and SPN-448 in earlier stages for ADHD/CNS and narcolepsy treatment, respectively, illustrate the company’s dedication to expanding its array of CNS therapies.
Contact Information
Address: 9715 Key West Avenue
Phone: 301 838 2500
Website: https://www.supernus.com
